Share on StockTwits

Shares of Renishaw plc (LON:RSW) have earned an average recommendation of “Hold” from the eight analysts that are covering the company, AnalystRatingsNetwork.com reports. Six equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is GBX 1,834.29 ($31.15).

A number of analysts have recently weighed in on RSW shares. Analysts at Numis Securities Ltd upgraded shares of Renishaw plc to an “add” rating in a research note on Wednesday, July 23rd. They now have a GBX 1,750 ($29.72) price target on the stock. Separately, analysts at N+1 Singer reiterated a “hold” rating on shares of Renishaw plc in a research note on Wednesday, July 23rd. They now have a GBX 1,690 ($28.70) price target on the stock. Finally, analysts at Investec upgraded shares of Renishaw plc to a “buy” rating in a research note on Tuesday, July 22nd. They now have a GBX 1,810 ($30.74) price target on the stock.

Shares of Renishaw plc (LON:RSW) traded down 0.48% during mid-day trading on Wednesday, hitting GBX 1850.00. 24,531 shares of the company’s stock traded hands. Renishaw plc has a 1-year low of GBX 1470.00 and a 1-year high of GBX 2240.00. The stock has a 50-day moving average of GBX 1652. and a 200-day moving average of GBX 1830.. The company’s market cap is £1.347 billion.

The company also recently declared a dividend, which is scheduled for Monday, October 20th. Stockholders of record on Wednesday, September 17th will be given a dividend of GBX 29.87 ($0.51) per share. This represents a yield of 1.64%. The ex-dividend date of this dividend is Wednesday, September 17th.

Renishaw plc is a metrology company. The Company is engaged in the design, manufacture and sale of advanced precision metrology and inspection equipment together with products for the healthcare sector, including Raman spectroscopy systems, dental systems, molecular diagnostic equipment and neurosurgical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.